海洛因滥用者唾液中毒品代谢物的SPE-GC/MS-SIM分析

本文首先考查了不同类型不同厂家的固相萃取柱的萃取效果,采用提取效果较好的50 mg/mL的Clean-screen CSDAUL01混合型强阳离子固相萃取柱,对唾液中的吗啡、可待因、6-单乙酰吗啡等3种鸦片类毒品进行提取后,将提取液吹干;再经MBTFA衍生化后,进行GC/MS-SIM检测。以乙基吗啡为内标,3种毒品的线性相关系数均大于0.99,线性范围为10～1000 ng/mL,相对回收率分别为85%～110%、94%～107%和75%～92%;相对标准偏差小于10%。3种毒品的检测限分别为2 ng/mL、1 ng/mL和2 ng/mL。该方法灵敏度高、重现性好、操作简便,可用于鸦片类毒品滥用者及中毒者唾液中的毒品及其代谢物的检测。     

超高效液相色谱-串联质谱法检验腐败血中吗啡和6-单乙酰吗啡

采用改良的QuEChERS前处理方法，建立了同时检验腐败血中吗啡和6-单乙酰吗啡的超高效液相色谱-串联质谱（UPLC-MS/MS）方法。腐败血中加入乙腈-水（4：1，v/v）混合溶液、30 mg NaCl和60 mg MgSO₄盐析促进相分离，最后经25 mg N-丙基乙二胺（PSA）和25 mg MgSO₄净化。选用ZORBAX Eclipse Plus C₁₈色谱柱分离，0.01%（v/v）氨水和乙腈作为流动相进行梯度洗脱，电喷雾电离正离子（ESI⁺）模式扫描，多反应监测（MRM）模式检测。结果表明，吗啡和6-单乙酰吗啡在5~200 μg/L范围内线性关系良好，相关系数（r²）≥ 0.9957，检出限（S/N=3）均为1 μg/L，定量限（S/N=10）均为5 μg/L。3个加标水平（5、100和200 μg/L）下，吗啡和6-单乙酰吗啡的平均加标回收率分别为81.84%~103.44%和81.03%~104.46%，日内和日间精密度（RSD）均小于12%，基质效应为83.04%~107.61%。方法简便、灵敏、可靠，可实现腐败血中吗啡和6-单乙酰吗啡的快速定性定量检验。     

海洛因与甲基苯丙胺毒品滥用者毛发特征分析的比较

根据海洛因和甲基苯丙胺滥用者毛发中毒品及其代谢物的分布特点,通过实验比较了两类毒品滥用者毛发的分析特点。海洛因吸食者毛发采用甲醇超声释放待测物,而后直接调整pH值进行液相萃取,萃取物挥干后进行衍生化并进行GC/MS检测;甲基苯丙胺吸食者毛发在碱性条件下消解,然后采用小体积萃取,直接在提取液中衍生化,并进行GC/MS检测。通过空白毛发标准添加6-单乙酰吗啡、吗啡和可待因进行分析,3种鸦片类毒品最小检测限均小于3μg/g,RSD(n=5)为2.5%~9.6%;通过空白毛发标准添加苯丙胺、甲基苯丙胺、3,4-(亚甲二氧基)苯丙胺和3,4-(亚甲二氧基)-甲基苯丙胺进行分析,4种苯丙胺类毒品的最小检测限为0.05μg/g,RSD(n=5)为5%~14%。     

海洛因与甲基苯丙胺毒品滥用者毛发特征分析的比较

根据海洛因和甲基苯丙胺滥用者毛发中毒品及其代谢物的分布特点,通过实验比较了两类毒品滥用者毛发的分析特点。 海洛因吸食者毛发采用甲醇超声释放待测物,而后直接调整pH值进行液相萃取,萃取物挥干后进行衍生化并进行GC/MS检测;甲基苯丙胺吸食者毛发在碱性条件下消解,然后采用小体积萃取,直接在提取液中衍生化,并进行GC/MS检测。 通过空白毛发标准添加6-单乙酰吗啡、吗啡和可待因进行分析,3种鸦片类毒品最小检测限均小于 3 μg/g,RSD(n=5)为2.5%~9.6%;通过空白毛发标准添加苯丙胺、甲基苯丙胺、3,4-(亚甲二氧基)苯丙胺和3,4-(亚甲二氧基)-甲基苯丙胺进行分析,4种苯丙胺类毒品的最小检测限为0.05 μg/g,RSD(n=5)为5%~14%。     

固相萃取-超临界流体色谱-质谱联用同时快速测定中成药和保健食品中的12种抗过敏化学药物

建立了固相萃取-超临界流体色谱-质谱联用（SPE-SFC-MS/MS）快速检测中成药和保健食品中12种抗过敏化学药物的分析方法。样品经甲醇超声提取,Oasis MCX固相萃取柱净化。采用Waters Trefoil CEL1色谱柱（150 mm×3.0 mm,2.5 μ m）,以CO₂为流动相A,甲醇-氨水（100：0.1,v/v）为流动相B,进行梯度洗脱。流速为1.2 mL/min,柱温和背压分别为45℃和12.4×10⁶ Pa。12种抗过敏化学药物以电喷雾离子源在正离子或负离子模式下用多反应监测（MRM）方式进行监测,整个分析过程在10 min内完成。结果表明,12种化学药物在5~250 μ g/L范围内线性关系良好,相关系数（r）均≥ 0.998,检出限（LOD）为0.141~0.262 μ g/L,定量限（LOQ）为0.703~1.308 μ g/L。3种加标水平（10、20和100 μ g/L）下,12种化学药物的平均回收率为76.1%~112.5%,相对标准偏差（RSD）为1.1%~8.3%。该法简便,灵敏性高,实用性强,可用于抗过敏类中成药和保健食品中非法添加抗过敏化学药物的检测。     

超高效液相色谱-串联质谱法检测唾液中3种毒品及其代谢物

建立了超高效液相色谱-串联质谱测定唾液中甲基苯丙胺、吗啡、O6-单乙酰吗啡等3种毒品及其代谢物的方法。以乙腈为提取液沉淀蛋白质法提取,采用基质提取溶液配制标准溶液制作定量曲线。采用BEH HILIC超高效液相色谱柱对待测毒品进行分离;采用电喷雾离子源正离子(ESI+)模式和多反应监测(MRM)模式进行质谱分析,以被测毒品的同位素内标进行定量。结果表明,在10、20、50、100 μg/L 4个添加水平下的回收率范围为(68.7±6.5)%～(110.8±4.6)%,日内精密度小于16.5%,日间精密度小于16.3%; 3种毒品的检出限(LOD,以信噪比(S/N)＞3计)和定量限(LOQ,以S/N＞10计)分别为0.02～0.05 μg/L和0.1～0.2 μg/L。方法快速、简便、定量准确、灵敏度高;在1 h之内即可对采集的唾液样品进行毒品定性和定量分析,可用于涉嫌吸毒者的快速认定。     

固相萃取-超快速液相色谱-串联质谱法同时测定血液中的4种苏丹染料

建立了血液样品中4种苏丹染料（苏丹Ⅰ、Ⅱ、Ⅲ和Ⅳ）的固相萃取-超快速液相色谱-串联质谱（UFLC-MS/MS）测定方法。样品经乙腈涡旋振荡提取,上清液加等体积水稀释混匀后移入C18固相萃取小柱净化,采用Agilent Eclipse Plus C18色谱柱（100 mm×2.1 mm,1.8 μm）以0.1%（v/v）甲酸水溶液和0.1%（v/v）甲酸乙腈溶液为流动相梯度洗脱分离,电喷雾电离（ESI）正离子多反应监测模式进行定量分析。讨论了苏丹Ⅲ和苏丹Ⅳ的偶氮基团E-Z光学异构现象,并对影响因素进行了分析。结果4种苏丹染料在0.1~20.0 μg/L范围内线性关系良好,相关系数均大于0.999;在低、中、高3个加标水平的平均回收率为93.0%~108.2%,相对标准偏差为4.8%~9.5%;方法的检出限（LOD）为0.06 μg/L,定量限（LOQ）为0.2 μg/L。本方法准确、快速、灵敏,可用于血液样品中苏丹类染料的检测分析。     

毛细管电泳pH酸修饰在线富集方法检测唾液中鸦片类毒品

建立了唾液中鸦片类毒品吗啡、可待因和6-单乙酰吗啡的毛细管电泳pH酸修饰在线富集方法,并进行了方法学考察。100mmol/L的磷酸盐缓冲液(含20%甲醇和5%异丙醇)作为背景缓冲液,10kV下电迁移进样99s,然后电迁移(2kV,2s)引入一段100mmol/L的盐酸区带,最后施加25kV电压进行分离检测。3种毒品在20～1 000ng/mL范围内具有良好的线性关系,r为0.9934～0.9998,检出限均为7ng/mL,相对标准偏差(RSD)<19%(n=5)。该方法样品前处理简单,只需用甲醇稀释样品便可进样分析,方法灵敏度较高、稳定性较好,可用于生物检材中痕量鸦片类毒品的检验。     

气相色谱-负化学源-质谱法检测水中10种全氟羧酸化合物

建立了气相色谱-负化学源-质谱（GC-NCI-MS）检测水中10种全氟羧酸化合物的分析方法。使用硅烷衍生化试剂N-甲基-N-三甲基硅基三氟乙酰胺（MSTFA）对全氟羧酸化合物进行衍生化，水样经弱阴离子交换固相萃取柱净化富集后进样。实验优化了样品前处理、衍生化和仪器条件。结果表明，10种全氟羧酸化合物在0.1~10 mg/L范围内线性关系良好，相关系数为0.9956~0.9993；方法的检测限（LOD）和定量限（LOQ）分别为0.5~1.5 μg/L和1.5~4.5 μg/L。在空白水样中进行了3个添加水平的加标回收试验，10种全氟羧酸化合物的平均回收率为70.2%~112.6%，相对标准偏差（RSD）为2.1%~14.5%（n=6）。该法原理简单，灵敏度高，准确、精密，可实现水体中10种全氟羧酸化合物同时检测的要求。     

超高效液相色谱-三重四极杆质谱法测定血浆和尿液中马桑亭和马桑宁

建立了超高效液相色谱-三重四极杆质谱联用技术测定血浆和尿液中马桑中毒标志物马桑亭和马桑宁的方法。血浆和尿液样品经固相支持液液萃取法提取净化后，溶于15%（v/v）甲醇水溶液中，以Cortecs C₁₈色谱柱（100 mm×2.1 mm，1.6 μm）作为分析柱进行分离，电喷雾负离子多反应监测（MRM）模式下检测，以氟苯尼考作为内标物，基质工作曲线内标法定量。血浆和尿液中马桑亭和马桑宁的平均加标回收率为86.2%~110%，相对标准偏差为5.1%~14.6%（n=6），血浆中马桑亭和马桑宁的检出限（S/N=3）分别为0.01 μg/L和0.1 μg/L，尿液中马桑亭和马桑宁的检出限分别为0.03 μg/L和0.3 μg/L。本法简单、灵敏、准确，可用于血浆和尿液中马桑亭和马桑宁的中毒检测。     

Quantification of atrazine and its metabolites in urine by on-line solid-phase extraction–high-performance liquid chromatography–tandem mass spectrometry

We have developed a method using on-line solid-phase extraction–high-performance liquid chromatography–tandem mass spectrometry (SPE-HPLC-MS/MS) and isotope dilution quantification to measure atrazine and seven atrazine metabolites in urine. The metabolites measured were hydroxyatrazine, diaminochloroatrazine, desisopropylatrazine, desethylatrazine, desethylatrazine mercapturate, atrazine mercaturate and atrazine itself. Our method has good precision (relative standard deviations ranging from 4 to 20% at 5, 10 and 50 ng/mL), extraction efficiencies of 67 to 102% at 5 and 25 ng/mL, relative recoveries of 87 to 112% at 5, 25, 50 and 100 ng/mL limits of detection (LOD) ranging from 0.03 to 2.80 ng/mL. The linear range of our method spans from the analyte LOD to 100 ng/mL (40 ng/mL for atrazine and atrazine mercapturate) with R ² values of greater than 0.999 and errors about the slope of less than 3%. Our method is rapid, cost-effective and suitable for large-scale sample analyses and is easily adaptable to other biological matrices. More importantly, this method will allow us to better assess human exposure to atrazine-related chemicals. Figure A schematic representation showing the elution of the analytes from the solid-phase extraction cartridge onto the analytical column for chromatographic separation prior to MS/MS analysis     

Solid-phase Extraction for Analysis of Short-Chain Chlorinated Paraffins in Water Samples

A method for analysis of short-chain chlorinated paraffins (SCCPs) in water based on solid-phase extraction (SPE) was established using electron capture negative chemical ionization mass spectrometry (GC-ENCI-MS). The SPE parameters, including the sorbent, eluent and elution volume were optimized. The Agilent Bond Elut-C₁₈ was precleaned with 3 mL of hexane and 3 mL of methanol, and subsequently conditioned with 3 mL H₂O prior to use. After the water samples were enriched by the cartridge, the sample was washed with 3 mL of 10% (V/V) methanol and eluted with 3 mL of hexane-dichloromethane (1:1, V/V) solution. The results indicated that the limits of detection (LOD) for SCCPs were 18 ng L^?1, while the corresponding limits of quantitation (LOQ) were 60 ng L^?1. The spiked recovery range was 90%–135%, with a relative standard deviation of less than 10%. Finally, 20 surficial water samples around Beijing were collected and SCCPs contents were analyzed using the proposed method. The SCCPs concentrations ranged from less than LOD to 682 ng L^?1 with a mean concentration of 216 ng L^?1.     

Quantification of fexofenadine in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry using mosapride as internal standard

A rapid high-performance liquid chromatography/positive ion electrospray tandem mass spectrometry method was developed and validated for the quantification of fexofenadine in human plasma using mosapride as internal standard. Following solid-phase extraction, the analytes were separated using an isocratic mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M+H]+ ions, m/z 502/466 for fexofenadine and m/z 422/198 for the IS. The method exhibited a linear dynamic range of 1-500 ng/mL for fexofenadine in human plasma. The lower limit of quantification was 1 ng/mL with a relative standard deviation of less than 5% for fexofenadine. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The total chromatographic run time of 2 min for each sample made it possible to analyze more than 400 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies.     

Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of fluvastatin in human plasma: validation and its application to pharmacokinetic studies

A simple, sensitive and rapid high-performance liquid chromatography/negative ion electrospray tandem mass spectrometry method was developed and validated for the assay of fluvastatin in human plasma. Following solid-phase extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by mass spectrometry in the multiple reaction monitoring mode using the respective [M-H]- ions, m/z 410/348 for fluvastatin and m/z 480/418 for the internal standard. The assay exhibited a linear dynamic range of 2-500 ng/mL for fluvastatin in human plasma. The lower limit of quantification was 2 ng/mL with a relative standard deviation of less than 5%. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. A run time of 1.5 min for each sample made it possible to analyze more than 400 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies.     

Simultaneous analysis of gemfibrozil,morphine, and its two active metabolites in different mouse brain structures using solid‐phase extraction with ultra‐high performance liquid chromatography and tandem mass spectrometry with a deuterated internal standard

A rapid and sensitive bioassay was established and validated to simultaneously determine gemfibrozil, morphine, morphine‐3β‐glucuronide, and morphine‐6β‐glucuronide in mouse cerebrum, epencephalon, and hippocampus based on ultra‐high performance liquid chromatography and tandem mass spectrometry. The deuterated internal standard, M6G‐d3, was mixed with the prepared samples at 10 ng/mL as the final concentration. The samples were transferred into the C₁₈ solid‐phase extraction columns with gradient elution for solid‐phase extraction. The mobile phase consisted of methanol and 0.05% formic acid (pH 3.2). Multiple reaction monitoring has been applied to analyze gemfibrozil (m/z 249.0 → 121.0) in anion mode, and M6G‐d3 (m/z 465.1 → 289.1), morphine (m/z 286.0 → 200.9), and M3G and M6G (m/z 462.1 → 286.1) in the positive ion mode. The method has a linear calibration range from 0.05 to 10 ng for gemfibrozil, morphine, and M3G and M6G with correlation coefficients >0.993. The lower limit of quantitation for all four analytes was 0.05 ng/mL, relative standard deviation of intra‐ and interday precision was less than 10.5%, and the relative error of accuracy was from ?8.2 to 8.3% at low, medium, and high concentrations for all the analytes. In conclusion, gemfibrozil can influence the morphine antinociception after coronary heart disease induced chronic angina by the change in one of morphine metabolites', M3G, distribution in mouse brain.     

Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study

To support the pharmacokinetic and bioavailability study of a once-daily fexofenadine/pseudoephedrine combination, a high-performance liquid chromatography/positive ion electrospray tandem mass spectrometry (HPLC/ESI-MS/MS) method for the simultaneous quantification of fexofenadine and pseudoephedrine was developed and validated with 500 microL human plasma using mosapride as an internal standard (IS). Following solid-phase extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M+H]+ ions, m/z 502/466 for fexofenadine, m/z 166/148 for pseuoephedrine and m/z 422/198 for the IS. The method exhibited linear dynamic ranges of 1-500 ng/mL and 2-1000 ng/mL for fexofenadine and pseudoephedrine, respectively, in human plasma. The lower limits of quantification were 1 and 2 ng/mL with a relative standard deviation of less than 10% for fexofenadine and pseudoephedrine, respectively. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The total chromatographic run time was 2 min and more than 400 human plasma samples could be analyzed in one day by running the system overnight. The method is precise and sensitive enough for its intended purpose.     

Quantification of pseudoephedrine in human plasma by LC-MS/MS using mosapride as internal standard

A simple, sensitive and rapid high-performance liquid chromatography/positive ion electrospray tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of pseudoephedrine in human plasma using mosapride as internal standard. Following solid-phase extraction, the analytes were separated using an isocratic mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple-reaction monitoring mode using the respective [M + H](+) ions, m/z 166/148 for pseuoephedrine and m/z 422/198 for the IS. The method exhibited a linear dynamic range of 2-1000 ng/mL pseudoephedrine in human plasma. The lower limit of quantification was 2 ng/mL with a relative standard deviation of less than 9% for pseudoephedrine. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The total chromatographic run time of 2 min for each sample made it possible to analyze more than 400 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies.     

Liquid chromatography/electrospray ionization mass spectrometry method for the quantification of valproic acid in human plasma

A simple, sensitive and rapid liquid chromatography/electrospray ionization mass spectrometry (LC/ESI-MS) method was developed and validated for the quantification of valproic acid, an antiepileptic drug, in human plasma using benzoic acid as internal standard (IS). Following solid-phase extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase C18 column and analyzed by MS in the single ion monitoring mode using the respective [M-H]- ions, m/z 143 for valproic acid and m/z 121 for the IS. The assay exhibited a linear dynamic range of 0.5-60 microg/mL for valproic acid in human plasma. The lower limit of quantification was 500 ng/mL with a relative standard deviation of less than 10%. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The average absolute recoveries of valproic acid and the IS from spiked plasma samples were 96.1+/-4.2 and 95.6+/-2.7%, respectively. A run time of 4.5 min for each sample made it possible to analyze more than 250 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability and bioequivalence studies.     

Liquid chromatography tandem mass spectrometry method for the quantification of amisulpride with LLOQ of 100 pg/mL using 100 microL of plasma

A sensitive and selective high-performance liquid chromatography-positive ion electrospray tandem mass spectrometry method was developed and validated for the quantification of amisulpride in 100 microL of human plasma. Following liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective (M + H)(+) ions, m/z 370-242 for amisulpride and m/z 341-112 for the internal standard. The assay exhibited a linear dynamic range with a lower range of 0.1-100 ng/mL and a higher range of 1-500 ng/mL of amisulpride in human plasma. The lower limit of quantification was 0.1 ng/mL with a relative standard deviation of less than 10%. Acceptable precision and accuracy were obtained for both linearity ranges. A run time of 2.0 min for each sample made it possible to analyze more than 275 human plasma samples per day. The validated method has been successfully used to analyze plasma samples for application in pharmacokinetic studies.